Synapse repair in alzheimer's disease and related dementias
Active Grant Awarded Last action
- Award ID
- R01AG096932
- Recipient
-
Buck Institute For Research On Aging UEI WMHWCFJNAJL3
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $785,081
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 4% complete
- Place of performance
- Novato, CA 94945, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute on Aging awarded Buck Institute For Research On Aging a grant of $785,081 on September 17, 2026, under Aging Research (CFDA 93.866) through Grant R01AG096932, "Synapse Repair in Alzheimer's Disease and Related Dementias." The project tests whether a KIBRA-based peptide can repair synapses and reverse memory loss in tauopathy by modulating protein kinase C phosphorylation of synapto-protective proteins. The recipient designed KBPEP, a small cell-permeable synthetic peptide derived from the KIBRA protein sequence, and Aim 1 determines its therapeutic impact on memory and in vivo plasticity in transgenic mouse models of tauopathy. The obligated amount is $785,081, and the ultimate completion date is July 31, 2031. Place of performance is Novato, California 94945. The Aging Research program supports biomedical, social, and behavioral research directed toward understanding the aging process and the diseases of aging, with the National Institute on Aging emphasizing ways to prevent and treat Alzheimer's disease and its related dementias.
Description
- Abstract
- Progressive cognitive decline in tauopathies, such as alzheimer's disease (ad), coincides with synapse deterioration in the brain. Synaptic mechanisms are critical modulators of cognition, yet little is known about how synapse function can impact the susceptibility of individuals to cognitive decline in tauopathy. Long-term potentiation (LTP) at synapses in the hippocampus, considered the physiological basis of memory formation, is impaired in tauopathy mouse models, and LTP impairment coincides with memory decline. Kidney/brain (KIBRA) is a postsynaptic protein that is required for hippocampus-dependent memory and for LTP expression at synapses. Reduced KIBRA protein levels in the human brain are associated with pathological TAU accumulation and cognitive impairment in with tauopathy. Our previous work on a transgenic mouse model of tauopathy demonstrated that overexpression of the C-terminal domain of the KIBRA protein can repair synaptic dysfunction and reverse cognitive impairments caused by pathogenic TAU. The KIBRA C-terminal domain interacts with protein kinase C (PKC) isoforms, which can phosphorylate synaptic proteins and modulate synapse strength. The potential applications of KIBRA for clinical translation in tauopathy have yet to be established. The central hypothesis of this proposal is that a KIBRA-based peptide can repair synapses and reverse memory loss in tauopathy by modulating the PKC phosphorylation of synapto-protective proteins. We designed a small cell permeable synthetic peptide derived from the KIBRA protein sequence (KBPEP) that protects against synaptic plasticity impairment, synapse loss, and memory deficits in a transgenic mouse model of hyperacetylated pathological TAU found in ad and other tauopathies (taukqhigh mice). In aim 1, we will determine the therapeutic impact of KBPEP on memory and in vivo plasticity in transgenic mouse models of tauopathy. In aim 2, we will determine the mechanistic impact of KBPEP on synaptic function across human induced pluripotent stem cell (IPSC)-derived neuron and transgenic mouse models of tauopathy. In aim 3, we will delineate how KBPEP affects PKC isoforms and the coordinated phosphorylation of proteins linked to the restorative effects on synapses in tauopathy models. Our studies represent a foundational step toward understanding how KIBRA can be developed into a therapeutic to restore synapse function and cognitive processes despite the toxicity and pathology in the brain in ad and ftld-TAU. These findings will provide valuable insights towards harnessing the therapeutic potential of KIBRA function to protect against cognitive decline in tauopathies.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $785,081 |
Quick answers
Who received award R01AG096932?
R01AG096932 was awarded to Buck Institute For Research On Aging by National Institute on Aging (National Institutes of Health) on September 17, 2026.
How much is award R01AG096932 worth?
$785,081 has been obligated on R01AG096932.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award